Rosen Law Firm Encourages Capricor Therapeutics Investors to Lead Securities Fraud Lawsuit

What's Happening?

Rosen Law Firm, a global investor rights law firm, is urging investors of Capricor Therapeutics, Inc. to consider leading a securities fraud lawsuit. The lawsuit alleges that Capricor provided misleading information about its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy. Investors who purchased securities between October 9, 2024, and July 10, 2025, may be entitled to compensation. The deadline to serve as lead plaintiff is September 15, 2025.

Why It's Important?

This lawsuit highlights the critical role of transparency and accuracy in corporate communications, especially in the biotech sector where investor decisions are heavily influenced by clinical trial data and regulatory progress. The outcome of this case could impact investor confidence in Capricor and similar companies, emphasizing the need for stringent compliance with securities laws. It also underscores the importance of legal recourse for investors who suffer losses due to corporate misrepresentations.